Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
HCV Advocate

Tuesday, October 25, 2011

Gilead and GlobeImmune Ally to Develop HBV Vaccine for Use in Combination with Viread

GlobeImmune is focused the development of therapeutic Tarmogen vaccines for the treatment of infectious diseases and cancer. Tarmogen vaccines are whole, heat-killed recombinant Saccharomyces cerevisiae yeast cells engineered to produce one or more target disease antigens, such as viral proteins or cancer-associated proteins. The company’s lead infectious disease product candidate, GI-5005, is a Tarmogen vaccine in Phase II development for the treatment of chronic hepatitis C infection (HCV).

The collaboration with Gilead aims to generate therapeutic vaccine products that have a specific HBV DNA antigens cloned into S. cerevisiae. The firms anticipate that combining a therapeutic vaccine with oral suppressive antiviral therapy will help increase surface antigen (HBsAg) loss with seroconversion. “Based on the proof-of-concept studies in hepatitis C infection, we believe that the combination of GlobeImmune’s Tarmogen immunotherapy products with oral suppressive antiviral therapy will help eliminate the cells harboring the hepatitis B virus, thus increasing seroconversion within a finite period,” remarks David Apelian, M.D., senior vp of R&D, and CMO at GlobeImmune.

Read more.....

No comments:

Post a Comment